89 related articles for article (PubMed ID: 29028349)
1. Proteomic Profiling of β-hCG-Induced Spheres in BRCA1 Defective Triple Negative Breast Cancer Cells.
Sengodan SK; Rajan A; Hemalatha SK; Nadhan R; Jaleel A; Srinivas P
J Proteome Res; 2018 Jan; 17(1):276-289. PubMed ID: 29028349
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 regulation on β-hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancer.
Sengodan SK; Nadhan R; Nair RS; Hemalatha SK; Somasundaram V; Sushama RR; Rajan A; Latha NR; Varghese GR; Thankappan RK; Kumar JM; Chil A; Anilkumar TV; Srinivas P
Oncogenesis; 2017 Sep; 6(9):e376. PubMed ID: 28869585
[TBL] [Abstract][Full Text] [Related]
3. β-hCG-induced mutant BRCA1 ignites drug resistance in susceptible breast tissue.
Sengodan SK; Hemalatha SK; Nadhan R; Somanathan T; Mathew AP; Chil A; Kopczynski J; Nair RS; Kumar JM; Srinivas P
Carcinogenesis; 2019 Nov; 40(11):1415-1426. PubMed ID: 30963174
[TBL] [Abstract][Full Text] [Related]
4. miR-342 overexpression results in a synthetic lethal phenotype in BRCA1-mutant HCC1937 breast cancer cells.
Crippa E; Folini M; Pennati M; Zaffaroni N; Pierotti MA; Gariboldi M
Oncotarget; 2016 Apr; 7(14):18594-604. PubMed ID: 26919240
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies.
Martinez-Outschoorn UE; Balliet R; Lin Z; Whitaker-Menezes D; Birbe RC; Bombonati A; Pavlides S; Lamb R; Sneddon S; Howell A; Sotgia F; Lisanti MP
Cell Cycle; 2012 Dec; 11(23):4402-13. PubMed ID: 23172369
[TBL] [Abstract][Full Text] [Related]
6. BRCA1 promoter hypermethylation in human placenta: a hidden link with β-hCG expression.
Nadhan R; Vaman JV; Sengodan SK; Hemalatha SK; Chellappan N; Sadasivan S; Pasuthottiyil Varkey A; Yesodharan S; Raji Sathyanpillai K; Bhuvaneswari Venugopal AK; Prameelakumari Sreenivasan S; Rajan A; Latha NR; Varghese GR; Thankappan R; Achyutuni S; Sreekumar Usha JD; Vijayamma Anilkumar T; Srinivas P
Carcinogenesis; 2020 Jul; 41(5):611-624. PubMed ID: 31219560
[TBL] [Abstract][Full Text] [Related]
7. Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine.
Nhukeaw T; Temboot P; Hansongnern K; Ratanaphan A
BMC Cancer; 2014 Feb; 14():73. PubMed ID: 24507701
[TBL] [Abstract][Full Text] [Related]
8. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
[TBL] [Abstract][Full Text] [Related]
9. Wild-type BRCA1, but not mutated BRCA1, regulates the expression of the nuclear form of beta-catenin.
Li H; Sekine M; Tung N; Avraham HK
Mol Cancer Res; 2010 Mar; 8(3):407-20. PubMed ID: 20215423
[TBL] [Abstract][Full Text] [Related]
10. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo.
Tassone P; Di Martino MT; Ventura M; Pietragalla A; Cucinotto I; Calimeri T; Bulotta A; Neri P; Caraglia M; Tagliaferri P
Cancer Biol Ther; 2009 Apr; 8(7):648-53. PubMed ID: 19333003
[TBL] [Abstract][Full Text] [Related]
11. Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents.
Tassone P; Blotta S; Palmieri C; Masciari S; Quaresima B; Montagna M; D'Andrea E; Eramo OP; Migale L; Costanzo F; Tagliaferri P; Venuta S
Int J Oncol; 2005 May; 26(5):1257-63. PubMed ID: 15809716
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis.
Heublein S; Mayr D; Meindl A; Kircher A; Jeschke U; Ditsch N
J Exp Clin Cancer Res; 2017 Apr; 36(1):57. PubMed ID: 28427429
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human chorionic gonadotropin induces signaling pathways towards cancer prevention in the breast of BRCA1/2 mutation carriers.
Su Y; Dang NM; Depypere H; Santucci-Pereira J; Gutiérrez-Díez PJ; Kanefsky J; Janssens JP; Russo J
Eur J Cancer Prev; 2023 Mar; 32(2):126-138. PubMed ID: 35881946
[TBL] [Abstract][Full Text] [Related]
14. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells.
Tassone P; Tagliaferri P; Perricelli A; Blotta S; Quaresima B; Martelli ML; Goel A; Barbieri V; Costanzo F; Boland CR; Venuta S
Br J Cancer; 2003 Apr; 88(8):1285-91. PubMed ID: 12698198
[TBL] [Abstract][Full Text] [Related]
16. Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers.
Fkih M'hamed I; Privat M; Ponelle F; Penault-Llorca F; Kenani A; Bignon YJ
Cell Oncol (Dordr); 2015 Dec; 38(6):433-42. PubMed ID: 26392359
[TBL] [Abstract][Full Text] [Related]
17. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
[TBL] [Abstract][Full Text] [Related]
18. A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer.
Buckley NE; Haddock P; De Matos Simoes R; Parkes E; Irwin G; Emmert-Streib F; McQuaid S; Kennedy R; Mullan P
Oncotarget; 2016 Apr; 7(15):19884-96. PubMed ID: 26943587
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function.
Kumaraswamy E; Wendt KL; Augustine LA; Stecklein SR; Sibala EC; Li D; Gunewardena S; Jensen RA
Oncogene; 2015 Aug; 34(33):4333-46. PubMed ID: 25417703
[TBL] [Abstract][Full Text] [Related]
20. Increased sensitivity of BRCA defective triple negative breast tumors to plumbagin through induction of DNA Double Strand Breaks (DSB).
Nair RS; Kumar JM; Jose J; Somasundaram V; Hemalatha SK; Sengodan SK; Nadhan R; Anilkumar TV; Srinivas P
Sci Rep; 2016 May; 6():26631. PubMed ID: 27220670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]